Vamorolone

Vamorolone is a novel and fully synthetic glucocorticoid developed by Santhera Pharmaceuticals. It is used to manage inflammation and immune dysregulation in patients with Duchenne muscular dystrophy (DMD), a neuromuscular disorder characterized by the insidious regression of neuromuscular function and the most common form of muscular dystrophy in the United States. Corticosteroid therapy is the current standard of care for DMD despite relatively high rates of adverse effects. Vamorolone is positioned as having a more tolerable adverse effect profile than other corticosteroids owing to its unique receptor binding profile, thus providing an additional treatment option in patients for whom corticosteroid adverse effects are intolerable or otherwise unacceptable. It is grouped under the following drug class(es): Corticosteroids, Steroids and Systemic corticosteroids. Its therapeutic use is listed as anti-inflammatories. The directory classifies it as a commercial API with a synthetic source/manufacturing origin. Other names for this substance include Agamree and Vamorolonum. Its PubChem CID is 3035000.